Edaravone Injection

Component:
Edaravone 20ml/30mg

Character:
This product is colorless or almost colorless clear liquid.

Indications:

Acute cerebral infarction neuroprotectant, mainly used for the treatment of acute cerebral infarction caused by neurological damage, improve neurological symptoms and daily life movement disorders.

Usage and dosage:
A dose of 30mg, twice a day, was added into an appropriate amount of normal saline and diluted before intravenous infusion, which was finished within 30 minutes. A course of treatment lasted for less than 14 days, and the administration should be started within 24 hours after the onset of illness as far as possible.

Precautions:

1. Use with caution in patients with mild and moderate renal impairment (it may aggravate renal failure). 2. Use with caution in patients with liver function impairment (it may aggravate liver function impairment). 3. Use with caution in patients with heart disease (may aggravate heart disease, or may be accompanied by renal insufficiency). 4. Use with caution in elderly patients (several deaths have been reported). There have been cases of aggravated acute renal insufficiency or renal failure resulting in death. Therefore, multiple renal function tests should be conducted during the administration of this product. At the same time, close observation should be continued after the administration, and the administration should be stopped immediately and appropriate treatment should be carried out in case of symptoms such as decreased renal function or oliguria. In particular, there have been reports of multiple deaths in elderly patients (most of whom are over 80 years of age), and particular attention should be paid.
 

Medication for special population:

Attention for children:

Children should not use this product (due to lack of use experience, the safety of children cannot be determined).

Precautions during pregnancy and lactation:

1. Pregnant women or women at risk of pregnancy should not use this product (the safety of administration during pregnancy cannot be determined). 2. It is forbidden for lactating women. If necessary, lactation should be stopped during administration (distribution to milk has been reported in animal experiments).

Notes for the elderly:

Due to low physiological function in the elderly, drug administration should be stopped and properly treated when adverse reactions occur. In general, it should be used with caution in elderly patients (over 80 years old).